Clifford Chance
Clifford Chance advises Pfizer Inc. on its acquisition of ReViral Limited
23 June 2022
- Gareth Camp, Alanna Hunter, , Francesca Wilson, Antonio Folgore, Stephen Reese, Alex Walker, Sean Wood, Nelson Jung, Sam Parry, Stavroula Vryna, Deepaloke Chatterjee, Andrew Patterson, Howard Adler, , Florence Wong, , Nicola Hemsley, Philip Wagman,
- London
Clifford Chance advises Pfizer Inc. on its acquisition of ReViral Limited
Clifford Chance advised Pfizer Inc. ("Pfizer"), one of the world's largest biopharmaceutical companies, in connection with its acquisition of ReViral Limited ("ReViral") which completed on 9 June 2022. ReViral is a clinical-stage biopharmaceutical company focused on developing antiviral therapies that target Respiratory Syncytial Virus (RSV). RSV is a common respiratory pathogen which can lead to severe and life threatening lower respiratory tract infections causing an estimated number of 64 million infections annually.
The proposed acquisition seeks to further clinical development of therapies for RSV and support Pfizer's efforts to advance a vaccine candidate and medication to protect against RSV.
Clifford Chance's multidisciplinary team across offices in London and New York was led by partners Gareth Camp and Alanna Hunter (Corporate Transactions), supported by Meldah Pilusa, Francesca Wilson, Antonio Folgore and Natalie Faktor with: IP advice provided by Stephen Reese (partner) supported by Alex Walker and Sean Wood; antitrust advice provided by Nelson Jung (partner) supported by Sam Parry, Stavroula Vryna and Deepaloke Chatterjee; incentives and employment advice provided by Andrew Patterson (partner), Howard Adler (partner) and Alistair Windass (partner) supported by David Baxter, Florence Wong and Hector Male; and tax advice provided by Nicola Hemsley (partner) and Philip Wagman (partner) supported by Eli Bursky.
The mandate arose from the strength of the firm's relationship with Pfizer, with the Clifford Chance team having previously advised Pfizer in connection with several other transactions.
